News & Events zu Lipocine Inc (LPCN)LPCNLipocine Inc

Lipocine Reports Q2 Revenue of $2.4M

Reports Q2 revenue $2.4M vs. $123K last year. As of June 30, 2026, Lipocine had $23.3 million of unrestricted cash, cash equivalents, and marketable investment securities, compared to $14.9 million at December 31, 2025.

Lipocine Announces Phase 3 Trial Results for LPCN 1154

Lipocine announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 - oral brexanolone - for the treatment of postpartum depression, or PPD. LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D total score compared to placebo at hour 60 in the full analysis set and the primary was not met. The results showed LPCN 1154 to be well tolerated and demonstrated a favorable safety profile to support outpatient administration without the need for healthcare provider monitoring. No treatment-related severe or serious adverse events were reported; no cases of excessive sedation or loss of consciousness were observed; and no treatment-related discontinuations were reported. The company identified signals that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with PPD. While the company is waiting for feedback from the FDA on such designations, the company plans to preserve capital and engage with stakeholders, including investors, regulators, and advisors, to evaluate all options available to the company going forward. Such options may include, but are not limited to, continued development of LPCN 1154, including the potential submission of a validation study protocol, development of other product candidates, strategic transactions, partnerships, and other opportunities.

Lipocine Completes Final Patient Visit in Phase 3 Trial of LPCN 1154

Lipocine announced that the last patient has completed the final study visit in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The randomized, double-blind, placebo-controlled study enrolled a total of 90 patients with severe PPD, having an average baseline Hamilton depression rating scale of 28.3. LPCN 1154 has shown a positive safety profile, with all reported nervous system adverse events being mild to moderate in severity. Furthermore, there were no instances of drug discontinuation, excessive sedation, loss of consciousness, or drug-related serious adverse events.